Atlas Trials

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Clinical trial NCT04164758 · TERMINATED

Trial details

NCT number
NCT04164758
Sponsor
ACADIA Pharmaceuticals Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Parkinson's Disease
Start date
2019-10-23
Primary completion
2020-09-25
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.